MxA mRNA decrease preceding NAb detection in IFNβ‐treated MS patients

BACKGROUND: Multiple sclerosis (MS) patients treated with interferon beta (IFNβ) are at risk of a declining response to treatment because of the production of IFNβ‐neutralizing antibodies (NAbs). The expression of Myxovirus resistance protein A (MxA) mRNA is regarded as a marker of IFNβ bioactivity....

Descripción completa

Detalles Bibliográficos
Autores principales: Libertinova, Jana, Meluzinova, Eva, Matoska, Vaclav, Zajac, Miroslav, Kovarova, Ivana, Havrdova, Eva, Horakova, Dana, Tomek, Ales, Marusic, Petr, Bojar, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346526/
https://www.ncbi.nlm.nih.gov/pubmed/28293479
http://dx.doi.org/10.1002/brb3.644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346526/
https://www.ncbi.nlm.nih.gov/pubmed/28293479
http://dx.doi.org/10.1002/brb3.644

Ejemplares similares